

Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015

Myat Htut Nyunt, Thinzar Shein, Ni Ni Zaw, Soe Soe Han, Fauzi Muh, Seong-Kyun Lee, Jin-Hee Han, Kyaw Zin Thant, Eun-Taek Han,¹ Myat Phone Kyaw¹

Artemisinin resistance containment in Myanmar was initiated in 2011 after artemisinin-resistant *Plasmodium falciparum* malaria was reported. Molecular evidence suggests that asymptomatic malaria infections harboring drug resistance genes are present among residents of the Myanmar artemisinin resistance containment zone. This evidence supports efforts to eliminate these hidden infections.

The global burden of malaria has been decreasing in recent years as a result of high levels of control of the spread of infection, and the ultimate goal of malaria elimination by 2030 in all Greater Mekong Subregion countries in Southeast Asia seems attainable (1). However, artemisinin-resistant *Plasmodium falciparum* malaria has been reported in Cambodia, Thailand, Myanmar, Laos, and Vietnam (2). Chloroquine-resistant *P. vivax* malaria has also been confirmed in 10 countries, including Myanmar (3), and mutations in the mefloquine-resistance molecular marker (*pvmdr1* mutation) and sulfadoxine/pyrimethamine-resistance markers (*pvdhps*, *pvdhfr* mutations) have been reported in Myanmar (4).

A containment program for artemisinin-resistant malaria was initiated in 2011 according to the Global Plan for Artemisinin Resistance Containment. Areas where artemisinin resistance was documented were ranked as Tier I under the protocol, whereas areas where resistance was suspected were ranked as Tier II. After Myanmar artemisinin resistance containment (MARC) was initiated, malaria morbidity and mortality rates decreased dramatically, especially in MARC Tier I areas (5). However, there are no reports on the prevalence of asymptomatic infections, which may represent a reservoir of local malaria transmission. In this study, we aimed to determine the prevalence of asymptomatic malaria infection and to analyze drug-resistance markers in asymptomatic *P. falciparum* and *P. vivax* infections.

Author affiliations: Department of Medical Research, Yangon, Myanmar (M.H. Nyunt, T. Shein, N.N. Zaw, S.S. Han, K.Z. Thant, M.P. Kyaw); Kangwon National University, Chuncheon, South Korea (M.H. Nyunt, S.-K. Lee, J.-H. Han, F. Muh, E.-T. Han)

DOI: <http://dx.doi.org/10.3201/eid2303.161363>

The Study

As of 2014, the Tier I area of artemisinin resistance in Myanmar was composed of 52 townships; the remaining regions were designated as Tier II. In January 2015, we conducted a cross-sectional study of one of the Tier I areas of the MARC, Shwegyin Township (22°20'0"N, 95°56'0"E) (Figure; online Technical Appendix, <https://wwwnc.cdc.gov/EID/article/23/3/16-1363-Techapp1.pdf>).

Rapid diagnostic tests (RDTs) (HRP2 and *P. vivax*-specific pLDH-based RDT, SDFK80; Standard Diagnostics, Gyeonggi-do, South Korea), microscopy, and PCR were used to screen for asymptomatic malaria infection (online Technical Appendix). We examined 1,182 local residents, with a male:female ratio of 4:5 and a median age of 30 years (interquartile range 18–45 years). Among these residents, 549 (46.4%) had a history of malaria infection within the past 5 years. No clinical cases of malaria infection were detected during the survey period. Although we found no RDT-positive cases of malaria infection, we detected 2 *P. vivax* infections by microscopy, with parasite densities of 580 and 1,200 parasites/μL.

When we performed molecular detection for the 4 common malaria species (online Technical Appendix), the overall rate of asymptomatic malaria infection was 2.4% (28/1,180) and included 4 *P. falciparum*, 22 *P. vivax*, and 2 *P. malariae* infections. Although the overall prevalence of asymptomatic infection in these areas was not high, it was similar to that observed in the Thailand–Myanmar border area during 2013–2014 (6).

In this study, RDT and microscopy missed almost all the asymptomatic infections detected by PCR, indicating that only the molecular method is suitable for the detection of asymptomatic infections. Moreover, the asymptomatic cases were broadly distributed geographically throughout the study area. Most of the infections were in male patients (19/28, 67.8%) and in the working-age group. Neither sex nor occupation was identified as an associated factor for asymptomatic infection (online Technical Appendix Table 2).

The established artemisinin-resistance marker K13 (kelch 13 gene) and the associated markers *pfarps10* (*P. falciparum* apicoplast ribosomal protein S10), *pffd* (*P. falciparum* ferredoxin), and *pfmdr2* (*P. falciparum* multidrug-resistance protein 2) were analyzed in all asymptomatic

¹These authors contributed equally to this article.




Figure. The study site, Shwegyin Township, Myanmar, where molecular evidence of drug resistance in asymptomatic malaria infections was obtained. As of 2014, Myanmar artemisinin resistance containment areas were divided into Tier I (52 townships) and Tier II (all remaining townships).

P. falciparum cases. Nonsynonymous mutations in the propeller region of K13 were found to be associated with artemisinin resistance and associated delayed clearance of the parasite beyond 72 hours after treatment with artemisinin-based combination therapy (7). A previous study in the same region of patients with uncomplicated *P. falciparum* malaria indicated that 25.3% carried mutant K13 alleles (8). Markers that showed the underlying genetic background predisposing to the K13 mutant were also reported, including *pfarps10*, *pfdd*, *pfmdr2*, and *pfcr1*. Specific single nucleotide polymorphisms of these genes, such as V127M of *pfarps10*, D193Y of *pfdd*, and T484I of *pfmdr2*, were found at a similar prevalence as K13 mutations (9).

Among the 4 asymptomatic *P. falciparum* infections, 2 isolates showed K13 mutations (C580Y in 1 isolate and P574L in the other). C580Y is a well-known validated mutation, and P574L is a candidate marker for artemisinin resistance. Both mutations were reported only in locations in Southeast Asia where artemisinin resistance has been identified (2). Moreover, we observed the *pfarps10* mutation (V127M) in 2 of the cases, the *pfdd* mutation (D195Y) in 3 cases, and the *pfmdr2* (T484I) mutation in all 4 isolates (Table; online Technical Appendix Table 3). This molecular evidence suggests the presence of artemisinin resistance in asymptomatic isolates and calls for action toward eliminating this parasite reservoir.

Similarly, we analyzed all available drug-resistance molecular markers in *P. vivax* (10), such as *pvcr1* (*P. vivax* chloroquine-resistance transporter), *pvdhps* (*P. vivax* dihydropteroate synthase), *pvdhfr* (*P. vivax* dihydrofolate reductase), and *pvmdr1* (*P. vivax* multidrug-resistance protein 1), in all *P. vivax* infections. We conducted analysis by using nested PCR, followed by gene sequencing (online Technical Appendix).

Among the 22 asymptomatic *P. vivax* infections, we were unable to amplify *pvcr1*, *pvdhfr*, and *pvmdr1* in 1 isolate and *pvdhps* in 2 isolates. A high mutation rate was observed in known drug-resistance markers such as *pvcr1* K10 AAG insert (66.6%, 14/21), *pvdhps* (100.0%, 20/20), *pvdhfr* (100.0%, 21/21), and *pvmdr1* (100.0%, 21/21) (Table). Asymptomatic isolates in this study showed a higher mutation rate of the *pvcr1* AAG insert than those studied in neighboring countries such as Thailand (11), India (12), and China (10). In the *pvmdr1* gene, both Y976F and F1076L mutations were observed in 23.8% of cases and F1076L in 19.0% of cases; these rates were higher than those for China (10) and India (12) but lower than those for Thailand (13,14). Although antifolates are not the recommended antimalarial drugs for treatment of *P. vivax*, *pvdhfr* and *pvdhps* mutation rates were noticeable. This finding indicates that drug pressure in *P. vivax* malaria contributing to drug resistance also

Table. *Plasmodium falciparum* and *P. vivax* drug-resistance molecular markers in asymptomatic infections, Myanmar, 2015

| Target | Description* | No. isolates/total (%) |
|---|--|------------------------|
| kelch 13 (K13) | Wild | 2/4 (50.0) |
| | C580Y | 1/4 (25.0) |
| | P574L | 1/4 (25.0) |
| <i>P. falciparum</i> apicoplast ribosomal protein S10 (<i>pfarps10</i>) | Wild | 2/4 (50.0) |
| | V127M | 2/4 (50.0) |
| <i>P. falciparum</i> ferredoxin (<i>pfdd</i>) | Wild | 1/4 (25.0) |
| | D193Y | 3/4 (75.0) |
| <i>P. falciparum</i> multidrug-resistance protein 2 (<i>pfmdr2</i>) | Wild | 0/4 (0.0) |
| | T484I | 4/4 (100.0) |
| <i>P. vivax</i> chloroquine-resistance transporter (<i>pvcr-t</i>) | Wild | 7/21 (33.3) |
| | Mutant (AAG insert) | 14/21 (66.7) |
| <i>P. vivax</i> multidrug-resistance protein 1 (<i>pvmdr1</i>) | Wild (T, Y, F) (958, 976, 1076) | 0/21 (0.0) |
| | Double mutant (M, Y, L) | 4/21 (19.0) |
| | Single mutant (M, Y, F) | 12/21 (57.1) |
| | Triple mutant (M, F, L) | 5/21 (23.8) |
| <i>P. vivax</i> dihydropteroate synthase (<i>pvdhps</i>) | Wild (S, A, K, A) (382, 383, 512, 553) | 0/20 (0.0) |
| | Single mutant (S, G, K, A) | 4/20 (20.0) |
| | Double mutant (S, G, K, G) | 9/20 (45.0) |
| | Triple mutant (A, G, K, G) | 5/20 (25.0) |
| | Quadruple mutant (A, G, M, G) | 2/20 (10.0) |
| <i>P. vivax</i> dihydrofolate reductase (<i>pvdhfr</i>) | Wild (F, S, T, S) (57, 58, 61, 117) | 0/21 (0.0) |
| | Single mutant (L, S, T, S) | 1/21 (4.8) |
| | Double mutant (F, R, T, N) | 2/21 (9.5) |
| | Quadruple mutant (L/I, R, M, T) | 18/21 (85.7) |

*Numbers in parentheses indicate the amino acid position. Mutant amino acids are shown in bold. All sequences were aligned with 3D7 (*P. falciparum*) and Sal-1 (*P. vivax*) reference sequences from <http://www.plasmodb.org>.

needs to be considered in addition to emphasizing the artemisinin-resistant *P. falciparum* malaria.

One limitation of this study is the exclusive focus on the local residents in the MARC area, where all available control and prevention measures had already been implemented. Unlike the mobile and migrant population, local residents have not been a top priority for the artemisinin resistance containment program, leading to a niche of hidden infection. Moreover, blood pooling before DNA extraction was used in this study for molecular detection of malaria infection. Although this method is not ultrasensitive, it has a higher sensitivity than RDT and microscopy. The hidden asymptomatic infections and associated molecular markers for drug resistance among the asymptomatic cases detected in this study represent a threat to containment and elimination efforts with regard to drug-resistant parasites.

Conclusions

All countries in the Greater Mekong Subregion have set an ultimate goal of eliminating malaria by 2030. One of the main challenges to achieving this goal is hidden asymptomatic infection, which maintains a reservoir for local transmission of malaria (15). Critically, these asymptomatic infections may carry drug-resistance genes, including genes for artemisinin resistance. Our results indicated that drug-resistant malaria parasites may be spreading, even in the containment areas or (pre-)elimination areas; this issue should, therefore, be addressed at a policy level. Detection and elimination of asymptomatic infections are of vital importance. Our evidence highlights the need for a strategy

for eliminating drug-resistant malaria in asymptomatic infections in the containment areas.

Acknowledgments

We thank all participants in this study and local health authority personnel and staff from the Parasitology Research Division and Advanced Molecular Research Center, Department of Medical Research and Kangwon Malaria Research Lab, Kangwon National University, South Korea.

This study was supported by the Korea Association of Health Promotion (2016_02), the National Research Foundation of Korea (NRF) grant funded by the South Korea government (MSIP) (NRF-2014R1A2A1A11052079), and by the Basic Science Research Program through the NRF funded by the Ministry of Science, ICT and Future Planning (2015R1A4A1038666).

Dr. Nyunt is a research scientist in the Department of Medical Research, Republic of the Union of Myanmar, and is currently studying in Kangwon National University, Chuncheon, South Korea. His research interests include drug-resistant malaria and neglected tropical diseases.

References

1. World Health Organization. Strategy for Malaria Elimination in the Greater Mekong Subregion (2015–2030). WHO Regional Office for the Western Pacific; 2015 [cited 2016 Aug 16]. http://www.wpro.who.int/mvp/documents/strat_mal_elim_gms/en/
2. World Health Organization. Status report: Artemisinin and artemisinin-based combination therapy resistance. Geneva: The Organization; 2016 [cited 2016 Aug 16]. <http://apps.who.int/iris/handle/10665/208820>

3. World Health Organization. World Malaria Report 2015. Geneva: The Organization; 2015 [cited 2016 Aug 16]. <http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/>
4. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: The Organization; 2010 [cited 2016 Aug 16]. <http://www.who.int/malaria/publications/atoz/9789241500470/en/>
5. Township Health Department. Township Health Profile 2012: Shwegyin Township. Department of Health, Myanmar; 2013.
6. Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Jain A, Taghavian O, et al. Common asymptomatic and submicroscopic malaria infections in western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. *Malar J*. 2016;15:333. <http://dx.doi.org/10.1186/s12936-016-1393-4>
7. Arie F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature*. 2014;505:50–5. <http://dx.doi.org/10.1038/nature12876>
8. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al.; Tracking Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014;371:411–23. <http://dx.doi.org/10.1056/NEJMoa1314981>
9. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet*. 2015;47:226–34. <http://dx.doi.org/10.1038/ng.3189>
10. Lu F, Wang B, Cao J, Sattabongkot J, Zhou H, Zhu G, et al. Prevalence of drug resistance-associated gene mutations in *Plasmodium vivax* in Central China. *Korean J Parasitol*. 2012;50:379–84. <http://dx.doi.org/10.3347/kjp.2012.50.4.379>
11. Lu F, Lim CS, Nam D-H, Kim K, Lin K, Kim T-S, et al. Genetic polymorphism in *pvmdr1* and *pvcrt-o* genes in relation to in vitro drug susceptibility of *Plasmodium vivax* isolates from malaria-endemic countries. *Acta Trop*. 2011;117:69–75. <http://dx.doi.org/10.1016/j.actatropica.2010.08.011>
12. Ganguly S, Saha P, Guha SK, Das S, Bera DK, Biswas A, et al. In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in *pvmdr1* and *pvcrt-o* genes. *Antimicrob Agents Chemother*. 2013;57:1246–51. <http://dx.doi.org/10.1128/AAC.02050-12>
13. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, et al. Amplification of *pvmdr1* associated with multidrug-resistant *Plasmodium vivax*. *J Infect Dis*. 2008;198:1558–64. <http://dx.doi.org/10.1086/592451>
14. Rungsihirunrat K, Muhamad P, Chaijaroenkul W, Kuesap J, Na-Bangchang K. *Plasmodium vivax* drug resistance genes; *Pvmdr1* and *Pvcrt-o* polymorphisms in relation to chloroquine sensitivity from a malaria endemic area of Thailand. *Korean J Parasitol*. 2015;53:43–9. <http://dx.doi.org/10.3347/kjp.2015.53.1.43>
15. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic infection in *Plasmodium falciparum*-endemic populations: a systematic review and meta-analysis. *J Infect Dis*. 2009;200:1509–17. <http://dx.doi.org/10.1086/644781>

Address for correspondence: Eun-Taek Han, Department of Medical Environmental Biology and Tropical Medicine, Kangwon National University, Chuncheon-si, Gangwon-do, 200-701, South Korea; email: ethan@kangwon.ac.kr; etaekhan@gmail.com

Discover the world...

of Travel Health

www.cdc.gov/travel

Visit the CDC Travelers' Health website for up-to-date information on global disease activity and international travel health recommendations.

Department of Health and Human Services • Centers for Disease Control and Prevention

Molecular Evidence of Drug Resistance in Asymptomatic Malaria Infections, Myanmar, 2015

Technical Appendix

Study Population

We conducted this study in Shwegyin Township, Bago Region (22°20'0"N, 95°56'0"E) in January 2015 (Figure 1). According to 2014 census data, 107,462 persons were living in an area of 2,440.1 km². Because of the nearby gold mine, many migrant workers were working in this area, and malaria was identified as one of the major diseases in Shwegyin (1). Since 2011, Shwegyin Township has been defined as a Tier I area of Myanmar artemisinin resistance containment because of the evidence of delayed parasite clearance in therapeutic efficacy studies conducted in Shwegyin during 2009–2010 (2,3) with molecular evidence of K13 mutations, an artemisinin-resistance marker (Nyunt et al., unpublished data). Shwegyin has been selected as one of the townships targeted for a malaria elimination program initiated in Myanmar. In 2001, 14.1% of outpatients and 20.1% of inpatients in Shwegyin Hospital were infected with malaria. The trend of prevalence has been decreasing, however, resulting in 11.3% of outpatients and 3.5% of inpatients infected with malaria in 2010 and 1.2% and 0.1%, respectively, infected with malaria in 2014.

Study Procedures

We recruited the participants in this study by randomized cluster sampling in Shwegyin Township. Inclusion criteria included a minimum age of 6 years and being local residents in the study area for more than 3 years; both sexes were included. Because we aimed to know the status of asymptomatic infections in local residents, the migrant or mobile population was excluded. Persons who currently showed signs and symptoms of malaria were also not included in this study.

We obtained written informed consent from all the participants. All the patients with parasite infections detected by any method (rapid diagnostic test [RDT], microscopy, or molecular method) were treated according to the National Malaria Treatment Guideline. This study was approved by the Ethical Committee of the Department of Medical Research, Myanmar (approval no. 49/Ethics-2014). The study was also registered with ClinicalTrial.gov (identifier NCT02708199).

Sample Size Determination

The prevalence of asymptomatic infection in the study population was unknown. Based on the previous studies (4,5) conducted in Southeast Asia, we assumed the maximum possibility of infection was 25% in the study site. A required sample size was calculated by anticipated population proportion of asymptomatic infection (25%) among the population of 107,462 (as of the 2014 census), with marginal error (2.5%), and 95% CI. The minimum sample size required was 1,141; in this study, 1,182 participants were involved.

Sampling Procedure

Randomized cluster sampling method was used in this study. Shwegyin Township was selected according to the rationale described previously. Two of the 4 local health centers were randomly selected. All villages belonging to the local health centers were listed and 6 villages were randomly selected. Among these villages, a sampling interval was calculated to get the required blood samples in the villages, which we determined to be at least 191 per village. Household visits or meeting places were used to collect the samples, depending on the convenience of the participants.

Laboratory Procedures

We collected 1 mL of venous blood from the participant's forearm under aseptic conditions, using a disposable syringe. The blood was used for detection of asymptomatic infections.

Rapid Diagnostic Test

We detected malarial infection in all participants by *Pf*HRP2- and *Pv*-specific pLDH-based RDT (SDFK80; Standard Diagnostics, Gyeonggi-do, South Korea) and peripheral blood film examination to exclude malaria infection in the field. We used venous blood for malaria detection by RDT according to the manufacturer's instructions.

Malaria Microscopy

We followed the World Health Organization standardized protocol (6) for malaria microscopy. Briefly, 10% Giemsa was used to stain thick and thin blood films in the field for initial screening. In the main laboratory, another set of thick and thin blood films was stained with 3% Giemsa stain for confirmation and validation of the result. We prepared a fresh Giemsa stain dilution at least once a day and possibly more often, depending on the number of slides processed. We examined the Giemsa-stained thick and thin blood films at a magnification of 1,000× to identify the parasite species and to determine the parasite density. We calculated the parasite density, expressed as the number of asexual parasites per microliter of blood, by dividing the number of asexual parasites by the number of leukocytes counted and then multiplying by an assumed leukocyte density (6,000 leukocytes/μL). All slides were stained and checked by World Health organization–certified microscopists and validated by an expert microscopist. A blood slide was considered negative when examination of 1,000 leukocytes revealed no asexual parasites. Two qualified microscopists read all the slides independently, and parasite densities was calculated by averaging the 2 counts. Blood smears with discordant results (differences between the 2 microscopists' results in species diagnosis, in parasite density of >50%, or in the presence of parasites) were reexamined by a third, independent microscopist, and parasite density was calculated by averaging the 2 counts closest to each other.

Molecular Detection

We adapted the pooling strategy described previously (7). In brief, 20 μL from each of 10 samples was combined to make 1 pool of 200 μL whole blood. These pooled blood samples were designated for DNA extraction with QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) and eluted into a final volume of 100 μL. Ten microliters of the DNA eluent was used for *Plasmodium* genus-specific amplification of the 18S rRNA gene, as described elsewhere (8). Only *Plasmodium*-positive pools were included to do individual DNA extraction again; 1 μL of

the DNA eluent was used for individual genus and species identification for asymptomatic malaria infection by using genus and specific primer pairs (8).

Artemisinin Resistance Molecular Markers for *P. falciparum* Infection

We analyzed all the samples that tested positive for *P. falciparum* malaria infection for artemisinin-resistance molecular markers (9,10) such as K13 kelch genes (PF3D7_1343700), *pfarps10* (PF3D7_1460900.1), *pffd* (PF3D7_1318100), and *pfmdr2* (PF3D7_1447900) by using the pairs of primers (Table 1. The details for amplification of these targets are available at our institutional web page (<http://kmrl.kangwon.ac.kr/>).

We performed amplification with an Accupower Premix (Bioneer, Daejeon, South Korea) in a final volume of 20 μ L. The final volume included 250 nmol/L of each primer, 0.25 mmol/L of each dNTP, 10 mmol/L Tris-HCl (pH 9.0), 30 mmol/L MgCl₂, 1.0 units of Taq polymerase, and 2 μ L of genomic DNA template.

For nested-1 PCR amplification of the K13 kelch propeller gene, initial denaturation at 95°C for 5 min was followed by 35 cycles at 95°C for 30 s, 58°C for 1 min, 72°C for 1.5 min, and a final extension at 72°C for 10 min. Using 1 μ L of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 60°C for 1 min and 72°C for 1 min with 30 cycles.

For nested-1 PCR amplification of the *pfarps10* gene, initial denaturation at 95°C for 5 min was followed by 35 cycles at 95°C for 30 s, 58°C for 1 min, 72°C for 1.5 min, and a final extension of 72°C for 10 min. Using 1 μ L of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 62°C for 1 min and 72°C for 1 min with 30 cycles.

For nested-1 PCR amplification of the *pffd* gene, initial denaturation at 95°C for 5 min was followed by 35 cycles at 95°C for 30 s, 62°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min. Using 1 μ L of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 60°C for 1 min and 72°C for 1 min with 30 cycles.

For nested-1 PCR amplification of the *pfmdr2* gene amplification, initial denaturation at 95°C for 5 min was followed by 35 cycles at 95°C for 30 s, 58°C for 1 min, 72°C for 1.5 min, and a final extension at 72°C for 10 min. Using 1 µL of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 60°C for 1 min and 72°C for 1 min with 35 cycles.

We visualized the PCR products by 1% agarose gel electrophoresis stained with 0.05% Redsafe dye (iNtRON Biotechnology, Daejeon, South Korea). We purified the PCR products by using a MEGA quick-spin Total Fragment DNA Purification Kit (iNtRON Biotechnology) and sequenced them with primers from a commercial sequencing company (Genotech, Daejeon, South Korea). We compared all the nucleotide and amino acid sequences with the reference sequence of 3D7 version 3 (www.plasmodb.org) and aligned them by using software in the Lasergene Genomic Suite (MegAlign, version 7.1; DNASTar, Madison, WI, USA).

Drug Resistance Molecular Marker Analysis for *P. vivax* Isolates

We further analyzed all the *P. vivax* isolates for *pvprt-o* (*P. vivax* chloroquine resistance transporter gene, PVX_087980), *pvmdr1* (*P. vivax* multidrug resistance protein 1, PVX_080100), *pvdhps* (*P. vivax* hydroxymethyl pterinpyrophosphokinase dihydropteroate synthetase, PVX_123230), and *pvdhfr* (*P. vivax* dihydrofolate reductase thymidylate synthase, PVX_089950) by using the modified procedures described previously (11). We performed amplification by using an Accupower premix (Bioneer, Daejeon, South Korea) in a final volume of 20 µL, which included 250 nmol/L of each primers, 0.25 mmol/L of each dNTP, 10 mmol/L Tris-HCl (pH 9.0), 30 mmol/L MgCl₂, 1.0 units of Taq polymerase, and 2 µL of genomic DNA template and pairs of primers (Table 1).

For the *pvprt-o* PCR amplification, initial denaturation at 94°C for 10 min was followed by 35 cycles at 94°C for 30 s, 60°C for 45 s, 72°C for 1 min, and a final extension at 72°C for 10 min for nested-1 PCR. Using 1 µL of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 60°C for 45 s with 30 cycles of amplification.

For the *pvmdr1* PCR amplification, initial denaturation at 94°C for 10 min was followed by 35 cycles at 94°C for 30 s, 58°C for 45 s, 72°C for 2 min, and a final extension at 72°C for 10 min for nested-1 PCR. Using 1 µL of the nested-1 PCR product as a template, we applied the

same conditions for the nested-2 PCR except for an annealing temperature of 62°C for 45 s and extension at 72°C for 45 s with 33 cycles of amplification.

For the *pvdhps* PCR amplification, initial denaturation at 94°C for 10 min was followed by 40 cycles at 94°C for 30 s, 58°C for 45 s, 72°C for 1.5 min, and a final extension at 72°C for 10 min for nested-1 PCR. Using 1 µL of the nested-1 PCR product as a template, the same conditions were applied for the nested-2 PCR except for 35 cycles of amplification.

For the *pvdhfr* PCR amplification, initial denaturation at 94°C for 10 min was followed by 35 cycles at 94°C for 30 s, 58°C for 45 s, 72°C for 1 min, and a final extension at 72°C for 10 min for nested-1 PCR. Using 1 µL of the nested-1 PCR product as a template, we applied the same conditions for the nested-2 PCR except for an annealing temperature of 62°C for 30 s and extension at 72°C for 1 min with 30 cycles of amplification.

We visualized the PCR products by 1% agarose gel electrophoresis and staining with 0.05% Redsafe dye (iNtRON Biotechnology). We purified the PCR products by using a MEGA quick-spin Total Fragment DNA Purification Kit (iNtRON Biotechnology) and sequenced them with primers from a commercial sequencing company (Genotech).

Sequence Analysis and Statistics

We compared all the nucleotide and amino acid sequences with the reference sequence of K13 kelch protein (gene ID: PF3D7_1343700), *pfarps10* (PF3D7_1460900.1), *pffd* (PF3D7_1318100), *pfmdr2* (PF3D7_1447900), *pvcrt* (PVX_087980), *pvdhps* (PVX_123230), *pvdhfr* (PVX_089950), and *pvmdr1* (PVX_080100) from www.plasmodb.org and aligned them by using software in the Lasergene Genomic Suite (MegAlign, version 7.1). We used SPSS software (version 22.0, IBM SPSS Statistics, Armonk, NY, USA) for all statistical analysis. We compared the frequency of mutations and haplotypes of the target genes among the groups by using χ^2 and Fisher exact tests with a two-sided confidence interval at the 95% confidence level. The sequences were deposited at GenBank (accession nos. KX000945–KX000959 and KX384672–KX384687).

References

1. Township-Health-Department. Shwegyin Township Health Profile 2012: Department of Health, Myanmar; 2013.
2. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva, Switzerland; 2010 [cited 2016 Aug 16].
<http://www.who.int/malaria/publications/atoz/9789241500470/en/>
3. World Health Organization Country Office Myanmar. Strategic Framework for Artemisinin Resistance Containment in Myanmar (MARC) 2011–2015; 2011 [cited 2016 Aug 16].
<http://www.searo.who.int/myanmar/documents/MARCframeworkApril2011.pdf>
4. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, et al. The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. *Malar J.* 2015;14:381.
<http://dx.doi.org/10.1186/s12936-015-0906-x>
5. Starzengruber P, Fuehrer HP, Ley B, Thriemer K, Swoboda P, Habler VE, et al. High prevalence of asymptomatic malaria in south-eastern Bangladesh. *Malar J.* 2014;13:16.
<http://dx.doi.org/10.1186/1475-2875-13-16>
6. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009 [cited 2016 Aug 16]. <http://www.who.int/malaria/publications/atoz/9789241597531/en/>
7. Nyunt MH, Kyaw MP, Thant KZ, Shein T, Han SS, Zaw NN, et al. Effective high-throughput blood pooling strategy before DNA extraction for detection of malaria in low-transmission settings. *Korean J Parasitol.* 2016;54:253–9. <http://dx.doi.org/10.3347/kjp.2016.54.3.253>
8. Snounou G, Singh B. Nested PCR analysis of *Plasmodium* parasites. *Methods Mol Med.* 2002;72:189–203. <http://dx.doi.org/10.1385/1-59259-271-6:189>
9. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature.* 2014;505:50–5.
<http://dx.doi.org/10.1038/nature12876>
10. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet.* 2015;47:226–34.
<http://dx.doi.org/10.1038/ng.3189>

11. Lu F, Wang B, Cao J, Sattabongkot J, Zhou H, Zhu G, et al. Prevalence of drug resistance-associated gene mutations in *Plasmodium vivax* in central China. *Korean J Parasitol.* 2012;50:379–84.
<http://dx.doi.org/10.3347/kjp.2012.50.4.379>

Technical Appendix Table 1. Pairs of primers used for amplification of the drug resistance markers for asymptomatic malaria, Myanmar, 2015

| Target gene | PCR | Primer | Primer sequences, 5'→3' |
|-----------------------------------|----------|-------------|---|
| K13 (PF3D7_1343700) | Nested 1 | K13_1R | CGG AGT GAC CAA ATC TGG GA |
| | | K13_3NF | AGC GGA AGT AGT AGC GAG AA |
| | Nested 2 | K13_2F | GCC AAG CTG CCA TTC ATT TG |
| | | K13_3R | GCC TTG TTG AAA GAA GCA CA |
| <i>pfarps10</i> (PF3D7_1460900.1) | Nested 1 | PfARPS_F3 | TGC GAC TTT TAG GGT GTG GA |
| | | PfARPS_N2R | CAT GGT ACC ACT TTT TCT TTT CCA |
| | Nested 2 | PfARPS_F1 | TTG TAG CAG GCC CAA TTC CC |
| | | PfARPS_N2R2 | TCT GGG TAA TTT GAC ATT CAT |
| <i>pfdd</i> (PF3D7_1318100) | Nested 1 | PfFD_F1 | AGT TGT TCT ACA TGC GCA GC |
| | | PfFD_R1 | AAT GTG CGC TTG TAG TGC AT |
| | Nested 2 | PfFD_F2 | TGC GCA GCA AAA TTA GTC GAA |
| | | PfFD_R2 | CAT TCC CCA TTT CAA TCA TAT CCA |
| <i>pfmdr2</i> (PF3D7_1447900) | Nested 1 | Pfmdr2_F1 | TTT GTG GCC AAG CAA AAG GA |
| | | Pfmdr2_R1 | TCT TTG TCG TTC TCC TCC TGA |
| | Nested 2 | Pfmdr2_F8 | AGA GGT ACC GAG AGT GCT AA |
| | | Pfmdr2_R8 | AGA GCA CAT GTT GTA CCT GGT T |
| <i>pvcrt-o</i> (PVX_087980) | Nested 1 | Pvcrt_N2F | ACG GAA TCA ACC CGA ATC CA |
| | | Pvcg10_R | AGT TTC CCT CTA CAC CCG |
| | Nested 2 | Pvcrtto_F | TCC TTG CCG CTG ATT CTA CG |
| | | Pvcrtto_R | GGT AAC GTT CAT CGG GGG TT |
| <i>pvmr1</i> (PVX_080100) | Nested 1 | Pvmr1_F3 | GGA TAG TCA TGC CCC AGG ATT G |
| | | Pvmr1_R1 | CTT ATA TAC GCC GTC CTG CAC |
| | Nested 2 | Pvmr1_F3 | GGA TAG TCA TGC CCC AGG ATT G |
| | | Pvmr1_R3 | CAT CAA CTT CCC GGC GTA GC |
| <i>pvdhps</i> (PVX_123230) | Nested 1 | Pvdhps_F1 | AGG AAG CCA TTC GCT CAA C |
| | | Pvdhps_B | GAG ATT ACC CTA AGG TTG ATG TAT C |
| | Nested 2 | Pvdhps_D | GGT TTA TTT GTC GAT CCT GTG |
| | | Pvdhps_B | GAG ATT ACC CTA AGG TTG ATG TAT C |
| <i>pvdhfr</i> (PVX_089950) | Nested 1 | Pvdhfr_F1 | ATG GAG GAC CTT TCA GAT GTA TT |
| | | Pvdhfr_N1R | CGG GTT TTT CTC CCC CAC TT |
| | Nested 2 | Pvdhfr_F1 | ATG GAG GAC CTT TCA GAT GTA TT |
| | | Pvdhfr_R1 | CCA CCT TGC TGT AAA CCA AAA AGT CCA GAG |

Technical Appendix Table 2. Characteristics of 28 patients with asymptomatic malaria infection, Myanmar, 2015

| Patient no. | ID | Village | Age, y | Sex | Occupation | PCR result | Microscopy result, parasites/ μ L |
|-------------|-------|----------------|--------|-----|-------------------|----------------------|---------------------------------------|
| 1 | A954 | Let Pa Dan | 59 | F | Dependent | <i>P. vivax</i> | NS* |
| 2 | A878 | Let Pa Dan | 24 | F | Farmer | <i>P. vivax</i> | NS |
| 3 | A887 | Let Pa Dan | 23 | F | Farmer | <i>P. vivax</i> | NS |
| 4 | A894 | Let Pa Dan | 52 | M | Manual worker | <i>P. vivax</i> | NS |
| 5 | A903 | Let Pa Dan | 31 | F | Farmer | <i>P. vivax</i> | NS |
| 6 | A905 | Let Pa Dan | 19 | M | Student | <i>P. vivax</i> | NS |
| 7 | A910 | Let Pa Dan | 17 | M | Manual worker | <i>P. vivax</i> | NS |
| 8 | A808 | Maung Yone | 43 | M | Farmer | <i>P. falciparum</i> | NS |
| 9 | A799 | Maung Yone | 32 | M | Manual worker | <i>P. malariae</i> | NS |
| 10 | A850 | Maung Yone | 56 | M | Dependent | <i>P. malariae</i> | NS |
| 11 | A762 | Maung Yone | 28 | F | Farmer | <i>P. vivax</i> | NS |
| 12 | A857 | Maung Yone | 40 | M | Dependent | <i>P. vivax</i> | NS |
| 13 | A356 | Sate Ka Lay | 52 | M | Manual worker | <i>P. falciparum</i> | NS |
| 14 | A349 | Sate Ka Lay | 56 | F | Dependent | <i>P. vivax</i> | NS |
| 15 | A383 | Sate Ka Lay | 21 | M | Student | <i>P. vivax</i> | NS |
| 16 | A353 | Sate Ka Lay | 25 | M | Manual worker | <i>P. vivax</i> | 580 |
| 17 | A377 | Sate Ka Lay | 41 | M | Manual worker | <i>P. vivax</i> | NS |
| 18 | A409 | Tha-Yet-Chaung | 35 | M | Company staff | <i>P. vivax</i> | NS |
| 19 | A541 | Tha-Yet-Chaung | 26 | F | Farmer | <i>P. falciparum</i> | NS |
| 20 | A548 | Tha-Yet-Chaung | 29 | F | Farmer | <i>P. vivax</i> | NS |
| 21 | A624 | Tha-Yet-Chaung | 25 | M | Farmer | <i>P. vivax</i> | 1,200 |
| 22 | A661 | Tha-Yet-Chaung | 29 | M | Manual worker | <i>P. vivax</i> | NS |
| 23 | B1095 | Wae Gyi | 17 | M | Taxi cycle driver | <i>P. falciparum</i> | NS |
| 24 | A968 | Wae Gyi | 18 | M | Manual worker | <i>P. vivax</i> | NS |
| 25 | A031 | Win Ka Nane | 26 | F | Farmer | <i>P. vivax</i> | NS |
| 26 | A035 | Win Ka Nane | 9 | M | Student | <i>P. vivax</i> | NS |
| 27 | A107 | Win Ka Nane | 45 | M | Manual worker | <i>P. vivax</i> | NS |
| 28 | A032 | Win Ka Nane | 30 | M | Manual worker | <i>P. vivax</i> | NS |

*NS, not seen by microscopy.

Technical Appendix Table 3. Mutations in drug resistance molecular markers for 4 patients with asymptomatic *P. falciparum* malaria, Myanmar, 2015

| Patient no. | ID | K13 (kelch gene)* | <i>pfarps10</i> | <i>pffd</i> | <i>pfmdr2</i> |
|-------------|-------|-------------------|-----------------|---------------|---------------|
| 1 | A356 | P574 L | V127 M | D193 Y | T484 I |
| 2 | A541 | C580 Y | V127 M | D193 Y | T484 I |
| 3 | A808 | Wild | Wild | D193 Y | T484 I |
| 4 | B1095 | Wild | Wild | Wild | T484 I |

*Mutant amino acids are shown in bold. All of the sequences are aligned with 3D7 sequences retrieved from plasmodb.org.